Candidate TB vaccine in phase II/III trial

Tuberculosis remains the most deadly infectious diseases in the world. In particular, the growing number of multiresistant microbes is a cause of great concern to doctors and healthcare policymakers. At least a dozen candidate vaccines are currently undergoing clinical testing. One of them, VPM1002, has now been approved for use in a clinical efficacy trial. The trial is designed to test the vaccine’s efficacy and safety in patients in whom tuberculosis resurfaces following successful drug therapy. In addition, a phase II trial on newborns exposed to HIV has been completed with promising results.